Active central nervous system (CNS) metastases.
Central nervous system (CNS) metastases .
Patients with known symptomatic central nervous system metastases requiring steroids.
EXCLUSION CRITERIA FOR SECOND-LINE THERAPY: Known or suspected brain or central nervous system metastases, irrespective of prior treatment
EXCLUSION CRITERIA FOR THIRD-LINE THERAPY: Known or suspected brain or central nervous system metastases, irrespective of prior treatment
Symptomatic central nervous system metastases
Active central nervous system metastases
Central nervous system metastases
Active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of central nervous system [CNS] metastases or spinal cord compression are eligible if they are clinically stable for at least 4 weeks before first dose of investigational product and do not require high-dose steroid treatment).
History of seizure disorders or unstable central nervous system metastases
Central nervous system (CNS) metastases (brain or leptomeningeal)
Known central nervous system metastases
Uncontrolled central nervous system (CNS) metastases (previously treated with radiation and off steroids is acceptable)
Central nervous system (CNS) metastases or seizure disorder
Patients with known central nervous system metastases, including lymphomatous meningitis
Central nervous system metastases, including lymphomatous meningitis
Known central nervous system or visceral metastases
Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
Active central nervous system metastases and/or leptomeningeal disease
Symptomatic central nervous system metastases
Uncontrolled central nervous system metastases
Patients/subjects with suspected or known central nervous system metastases unless adequately treated
Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases
History or evidence of central nervous system (CNS) metastases (patients with pretreated metastases are eligible under certain conditions)
Patient has known active central nervous system metastases.
Active central nervous system (CNS) metastases.
Central nervous system (CNS) metastases: patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy and stable with no recurrent lesions for at least 3 months from the start of protocol therapy
Must not have suspected or known central nervous system metastases unless adequately treated
Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
Active uncontrolled central nervous system (CNS) metastases
Participant has known history or inflammatory bowel disease, pneumonitis, or known uncontrolled metastases to the central nervous system (CNS) (with certain exceptions).
Untreated central nervous system metastases; patients with a history of brain metastases must have had no central nervous system (CNS)-directed therapy within the past 60 days and radiological assessment within 30 days of study entry demonstrating a lack of progressive CNS disease
Any history of central nervous system (CNS) metastases that is not adequately treated with surgery or SABR > 14 days prior
Distant metastatic disease including central nervous system (CNS) or leptomeningeal metastases is not allowed
Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
Patient has central nervous system (CNS) metastases or seizure disorder
Patients may have central nervous system (CNS) metastases which have been treated and are radiographically stable for at least 4 weeks
Evidence of central nervous system (CNS) metastases
Previous radiotherapy for central nervous system metastases
Known central nervous system (CNS) metastases requiring treatment, such as surgery, radiation or steroids
Known cerebral metastases, central nervous system (CNS) or epidural tumor
Central nervous system (CNS) metastases or seizure disorder
Known central nervous system (CNS) metastases
Known central nervous system metastasis. Patients with history of central nervous system metastases are eligible if they are clinically or radiographically stable for at least 3 months and not taking steroids or anticonvulsants.
Presence of untreated or symptomatic central nervous system metastases, or central nervous system metastases that currently require local therapy (such as radiotherapy or surgery), or require doses of corticosteroids within the prior 4 weeks
Active central nervous system tumor or metastases
Presence of central nervous system (CNS) metastases
Known central nervous system brain metastases
Symptomatic central nervous system metastases
Active or history of central nervous system (CNS) metastases
Presence of known, active central nervous system (CNS) metastases
Any history of central nervous system (CNS) metastases that is not adequately treated (surgery or radiation) > 14 days prior to registration
Central nervous system (CNS) metastases or seizure disorder
Central nervous system (CNS) metastases if not stable for at least 2-3 months based on imaging, clinical assessment, use of steroids, or seizure disorder
Known central nervous system metastases
Patients must not have known active central nervous system (CNS) metastases; patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy, and stable with no recurrent lesions for at least 6 months
Distant metastatic disease including central nervous system (CNS) or leptomeningeal metastases is not allowed
Uncontrolled central nervous system metastases
Uncontrolled central nervous system metastases; treated, non-progressing central nervous system (CNS) disease (documented by brain magnetic resonance imaging [MRI]) off corticosteroids for at least 1 month are eligible
Patients with active central nervous system (CNS) metastases
Known central nervous system (CNS) metastases with active symptoms, or requiring anticonvulsive medications, or steroids
No brain or central nervous system (CNS) metastases
Active Central nervous system (CNS) metastases
Patient must have no prior history or current clinically apparent central nervous system metastases
Known central nervous system metastases or central nervous system as the only source of disease
Patient must not have a history of or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have had previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of PD 0332991
Presence of or known history of brain/central nervous system (CNS) tumor or metastases
Known central nervous system metastases or central nervous system as the only source of disease
At the time of Day 1 of the study, subjects with central nervous system (CNS) metastases must have been treated and must be asymptomatic
Uncontrolled central nervous system metastases
Has known active central nervous system metastases
Patients are ineligible if they have any history of central nervous system (CNS) metastases
Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids
Known brain or central nervous system metastases or history of uncontrolled seizures.
Individuals with known or suspected central nervous system metastases or individuals requiring chronic daily treatment with oral corticosteroids
Subject has uncontrolled metastases to the central nervous system (CNS).
Symptomatic central nervous system metastases (excluding Glioblastoma multiforrme (GBM) and Primary Central Nervous System Lymphoma (PCNSL). Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed.
Subjects with active central nervous system metastases
Known or suspected central nervous system metastases
Active central nervous system (CNS) metastases requiring treatment
Primary central nervous system (CNS) malignancy or active metastases within 5 years
Have confirmed presence of central nervous system metastases
Patients with known central nervous system metastases.
Active central nervous system (CNS) metastases
Patients with brain metastases must have at least one site of measurable disease outside of the central nervous system
Subjects with active central nervous system (CNS) metastases are excluded
Phase 1b: History or evidence of central nervous system (CNS) metastases
Central nervous system (CNS) metastases or seizure disorder
Central nervous system metastases
Patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
Active central nervous system (CNS) metastases.
Presence of known central nervous system or brain metastases
Patients with central nervous system (CNS) tumors or known brain metastases
Prior or concurrent central nervous system (CNS) metastases
Presence of symptomatic or uncontrolled brain or central nervous system metastases
Central nervous system (CNS) metastases
Central nervous system (CNS) disease, including treated brain metastases
Central nervous system (CNS) metastases
Asymptomatic, central nervous system metastases are permitted
No known central nervous system (CNS) metastases
Known history of central nervous system (CNS) metastases
Previous radiotherapy for cerebral metastases, central nervous system (CNS) or epidural tumor
Patients with known central nervous system (CNS) metastases, unless metastases are treated and stable and the patients do not require systemic steroids
Patient must not have a history of or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have had previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of pazopanib
Central nervous system metastases unless: (1) metastases have been treated and have remained controlled for at least two weeks following treatment, AND (2) patient has no residual neurological dysfunction off corticosteroids for at least one week; a CT or MRI to evaluate for central nervous system (CNS) disease is required for symptomatic patients only
Known central nervous system (CNS) metastases
Known or suspected brain or other central nervous system (CNS) metastases
Active central nervous system (CNS) metastases
History or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 2 months prior to first dose of study drug
Patients with central nervous system (CNS) metastases are eligible (as long as projected survival is > 6 months)
Active or history of central nervous system metastases.
Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)
Patient have uncontrolled brain metastases or central nervous system disease.
Active central nervous system metastases
History or known presence of central nervous system (CNS) metastases
Known central nervous system metastases
Known cerebral metastases, central nervous system (CNS) or epidural tumor
Central nervous system (CNS): no recent history (within 6 month) of cerebrovascular accident, transient ischemic attacks, central nervous system or brain metastases
Known active central nervous system (CNS) metastases.
Known or suspected brain or central nervous system metastases
Known central nervous system metastases
Symptomatic central nervous system metastases or lesions requiring treatment.
Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least 2 weeks and the subject is neurologically stable
Central nervous system metastases
Patients are excluded if they have a history of central nervous system (CNS) metastases
Central nervous system (CNS) metastases or seizure disorder
Known central nervous system (CNS) or brain metastases.
Known central nervous system (CNS) disease, other than stable, treated brain metastases
Known presence of central nervous system metastases
Central nervous system metastases
Any history or signs of central nervous system metastases;
CNS (Central Nervous System) tumors as well as history of brain metastases
Known brain tumors or Central nervous system (CNS) metastases
Active central nervous system tumors or metastases
History or presence of known central nervous system metastases
Known central nervous system (CNS) disease except for treated brain metastases
Subjects with known central nervous system metastases.
History of Central nervous system (CNS) or brain metastases
Uncontrolled central nervous system metastases
No evidence of central nervous system (CNS) metastases
Unstable metastases to the central nervous system (CNS)
Have a known history of central nervous system disease (e.g., brain metastases or a seizure disorder)
Participants with central nervous system (CNS) (e.g., brain or leptomeningeal) metastases.
Known central nervous system metastases or central nervous system as the only source of disease
Known or suspected brain or other central nervous system metastases
Presence of symptomatic central nervous system metastases.
Uncontrolled Central Nervous System (CNS) metastases
Known metastases to the central nervous system
Central nervous system (CNS) metastases